Related Experiment Video

Updated: Aug 23, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact

Tiyao Liu1, Zhongran Liu2, Wenjing Wei2

  • 1Shandong Key Laboratory of Intelligent Oil & Gas Industrial Software, Qingdao Institute of Software, College of Computer Science and Technology, China University of Petroleum (East China), Qingdao, Shandong, China.

Expert Opinion on Therapeutic Targets
|August 21, 2026
PubMed
Abstract

Insights

Targeting cyclin-dependent kinase 9 (CDK9) shows promise for treating cancers driven by transcriptional addiction. This review covers CDK9

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 9 (CDK9) regulates RNA polymerase II elongation.
  • CDK9 is a therapeutic target in transcriptionally dependent tumors.
  • Interest is growing in CDK9 inhibitors and degraders for cancer therapy.

Purpose of the Study:

  • To review the molecular functions of the CDK9/positive transcription elongation factor b (P-TEFb) axis.
  • To discuss CDK9's role in oncogenic programs and therapeutic strategies.
  • To explore inhibitors, degraders, biomarkers, combinations, and resistance mechanisms.

Main Methods:

  • Literature review of CDK9's role in cancer.
  • Summary of small-molecule inhibitors and PROTAC degraders.
  • Analysis of biomarkers, combination strategies, and resistance.

Main Results:

  • CDK9 inhibition induces apoptosis, epigenetic changes, and tumor microenvironment remodeling.
  • Small-molecule inhibitors and PROTAC degraders are emerging therapeutic modalities.
  • Biomarkers, combination strategies, and resistance mechanisms are key considerations.

Conclusions:

  • Selective CDK9 targeting is a promising strategy for refractory malignancies.
  • Therapeutic success depends on transcriptional dependency, biomarkers, and combination design.
  • Future development requires optimizing therapeutic index, biomarkers, and managing resistance.
Keywords:
CDK9PROTACclinical translationresistance mechanismstranscriptional addictiontumor microenvironment

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...